FDA accepts Merck’s sBLA for Keytruda six-week dosing schedule for melanoma and multiple other indications

This article was originally published here

Merck is seeking FDA approval of a 400 mg Q6W dose infused over 30 minutes for KEYTRUDA indications in melanoma, classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma,

The post FDA accepts Merck’s sBLA for Keytruda six-week dosing schedule for melanoma and multiple other indications appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply